ArticleAnnals of surgical oncology2025
Beyond the Scalpel: EGFR Mutation Predicts Intraoperative Blood Loss and Transfusion Needs During Lung Cancer-derived Spinal Metastasis Surgery.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundSurgical intervention for lung cancer-derived spinal metastasis (LCSM) is frequently associated with significant intraoperative hemorrhage.
objectiveThis prospective cohort study aimed to identify clinical predictors of intraoperative blood loss (IOBL) and red blood cell transfusion requirements in patients undergoing LCSM surgery.
methodsConsecutive patients treated surgically for LCSM at a tertiary medical center between January 2017 and August 2024 were prospectively enrolled. Demographic, surgical, and laboratory variables were evaluated, including epidermal growth factor receptor (EGFR) mutation status, metastatic burden, and coagulation profiles. Multivariable linear regression models were used to quantify associations with IOBL and transfusion volume.
resultsAmong 163 patients, mean IOBL was 765 ± 890 mL, with 54.6% requiring red blood cell transfusions (mean 4.9 ± 2.9 units). Transfused patients demonstrated 3.8-fold greater blood loss than their non-transfused counterparts (1151.7 vs 300.9 mL, p < 0.001). Key independent predictors of IOBL included EGFR mutation (β = 309.7 mL, p = 0.012), lumbar metastases (β = 288.7 mL, p = 0.038), surgical duration (168.7 mL/h, p < 0.001), laminectomy levels (284.3 mL/level, p < 0.001), and elevated preoperative international normalized ratio (β = 1156.9 mL, p = 0.018). Predictors of transfusion volume paralleled these findings, with EGFR mutation (β = 1.33 units, p = 0.002) and laminectomy levels (β = 0.75 units/level, p = 0.003) demonstrating dose-dependent relationships.
conclusionThis study identified EGFR mutation as a novel molecular predictor of hemorrhagic risk in LCSM surgery, independent of systemic therapy status. The quantifiable impact of procedural complexity and coagulation dysfunction provides actionable thresholds for preoperative optimization. These findings enable stratified blood management protocols, particularly for EGFR-mutated cohorts requiring multilevel decompression.
Indexed as
Identifiers
40987985What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.